PMID- 24457403
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20221207
IS  - 2520-8721 (Electronic)
IS  - 1109-3099 (Linking)
VI  - 12
IP  - 4
DP  - 2013 Oct-Dec
TI  - The prevalence of hypoglycemia and its impact on the quality of life (QoL) of 
      type 2 diabetes mellitus patients (The HYPO Study).
PG  - 550-8
AB  - OBJECTIVE: To estimate the impact of hypoglycemia on the Quality of Life (QoL) 
      and its prevalence in patients with type 2 diabetes mellitus (T2DM) in Greece. 
      DESIGN: A cross-sectional epidemiological study was conducted in 6631 patients 
      with T2DM. QoL was assessed with the patient self-administered ADDQoL-19. 
      Reliability analysis of patients' outcomes was performed to assess internal 
      consistency of the ADDQoL-19. Patients were categorized according to hypoglycemia 
      experience and diabetes control. Controlled patients were considered as having 
      Hb1Ac <7% (53 mmol/mol) and hypoglycemic episodes were defined as 
      laboratory-confirmed clinical symptomatic events. RESULTS: In total, 59% of the 
      sample had HbA1c >7% (53 mmol/mol) and 20.4% of patients had a history of 
      laboratory-confirmed hypoglycemia. The mean age was 60 years and the mean T2DM 
      duration was 10 years. The mean QoL score was -3.09+/-1.9 for the total sample and 
      the mean score of non-hypoglycemic patients was -3.05+/-2, while the respective 
      score of hypoglycemic patients was -3.26 +/-1.8, (p</=0.001). Similar results were 
      observed in the group of controlled and uncontrolled patients, who scored 
      -2.73+/-1.7 and -3.33+/-1.9, respectively (p</=0.001). Comparable results were 
      identified in the majority of the ADDQoL-19 instrument dimensions. CONCLUSIONS: 
      The QoL of T2DM patients is affected significantly by hypoglycemia and the level 
      of disease control. In diabetes treatment, the ultimate goal should be optimal 
      glycemic control without debilitating hypoglycemic episodes which compromise 
      patients' QoL.
FAU - Rombopoulos, Grigorios
AU  - Rombopoulos G
AD  - Medical Dept. & Health Economics, Novartis Hellas SA, Athens, Greece.
FAU - Hatzikou, Magdalini
AU  - Hatzikou M
AD  - Medical Dept. & Health Economics, Novartis Hellas SA, Athens, Greece.
FAU - Latsou, Dimitra
AU  - Latsou D
AD  - University of Athens, Political Science & Public Administration, Greece.
FAU - Yfantopoulos, John
AU  - Yfantopoulos J
AD  - University of Athens, Political Science & Public Administration, Greece.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Hormones (Athens)
JT  - Hormones (Athens, Greece)
JID - 101142469
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/*psychology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Greece
MH  - Humans
MH  - Hypoglycemia/blood/*epidemiology/etiology
MH  - Hypoglycemic Agents/adverse effects/therapeutic use
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Quality of Life/*psychology
EDAT- 2014/01/25 06:00
MHDA- 2014/09/30 06:00
CRDT- 2014/01/25 06:00
PHST- 2014/01/25 06:00 [entrez]
PHST- 2014/01/25 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - 10.14310/horm.2002.1443 [doi]
PST - ppublish
SO  - Hormones (Athens). 2013 Oct-Dec;12(4):550-8. doi: 10.14310/horm.2002.1443.